Welcome to our dedicated page for IDEXX LABORATORIES /DE SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEXX LABORATORIES /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEXX LABORATORIES /DE's regulatory disclosures and financial reporting.
IDEXX Laboratories entered into Amendment No. 2 to its fourth amended and restated credit agreement, dated November 12, 2025. The amendment adds a three‑year term loan facility and extends the revolving credit facility maturity to five years from the closing date.
The credit arrangement now consists of an unsecured $1.0 billion revolver and an unsecured $250 million term loan, with flexibility to add up to $250 million in incremental revolving commitments and/or term loans. Borrowings may be used for general corporate purposes.
Interest is benchmarked to currencies and tenors selected, with margins tied to the consolidated leverage ratio: for U.S. dollars, base rate or Adjusted Term SOFR/Daily Simple SOFR with margins ranging from 0.0%–1.375%. Comparable benchmarks apply for CAD (PRIMCAN/Term CORRA), EUR (EURIBOR) and AUD (BBSY). Obligations are guaranteed by certain U.S. subsidiaries, with future material U.S. subsidiaries required to guarantee. Covenants include a consolidated leverage ratio and customary negative covenants; events of default are customary, including a change of control.
IDEXX Laboratories (IDXX): Executive Vice President reports option exercises and stock sales. On 11/07/2025, the officer exercised non-qualified stock options to acquire 7,125 shares at $288.78 and 5,405 shares at $505.53. The insider then sold 5,114 shares at a weighted average price of $702.2017, 1,465 shares at $703.7339, 1,468 shares at $704.8659, and 1,378 shares at $705.5448.
Following these transactions, the officer beneficially owned 21,148.9435 shares directly, plus 160 shares held indirectly jointly with spouse. Derivative holdings reported as remaining include 1,604 options. Footnotes note weighted-average sale prices with full breakdowns available upon request and prior vesting schedules for the exercised options.
IDEXX Laboratories (IDXX): Director Joseph L. Hooley reported the acquisition of 39 deferred stock units on 10/30/2025 under the company’s Director Deferred Compensation Plan, coded “A.” The filing lists a reference price of $628.54 per share and states the units were issued in exchange for deferred cash compensation of $24,375.00.
Each deferred stock unit represents a contingent right to receive one share of common stock. The units vest immediately upon grant and are payable as common stock following the director’s resignation from the Board or at other nondiscretionary dates allowed by the plan. Following the transaction, 39 shares are beneficially owned directly.
IDEXX Laboratories reported higher third‑quarter results in its Form 10‑Q for the period ended September 30, 2025. Total revenue rose to $1,105,239 thousand from $975,543 thousand a year ago, driven by the Companion Animal Group, where CAG Diagnostics recurring revenue reached $873,273 thousand. Product revenue was $656,159 thousand and service revenue was $449,080 thousand.
Gross profit increased to $683,354 thousand from $596,038 thousand. Net income grew to $274,610 thousand, with diluted EPS of $3.40 compared with $2.80 last year. By category within CAG, IDEXX VetLab consumables were $387,813 thousand, reference laboratory services $362,725 thousand, and CAG Diagnostics capital instruments $51,479 thousand. Water revenue was $54,297 thousand and LPD revenue was $33,944 thousand.
Year‑to‑date operating cash flow was strong at $826,045 thousand. The company repurchased $979,190 thousand of common stock year‑to‑date and ended with cash and cash equivalents of $208,166 thousand. Borrowings under the Credit Facility totaled $455,000 thousand, and total debt (current and long‑term) was $524,822 thousand as of quarter‑end. Shares outstanding were 79,851,330 on October 29, 2025.
IDEXX Laboratories, Inc. announced quarterly results for the period ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details. The information was provided under Item 2.02 of Form 8‑K and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
IDEXX Laboratories director Karen Peacock filed an amended initial insider report to correct her stated holdings. The Form 3/A clarifies that she beneficially owns 1 share of common stock directly, which was inadvertently omitted from her original Form 3. The amendment does not reflect a new buy or sell transaction; it simply updates the ownership record.
IDEXX Laboratories (IDXX) filed a Form 3 showing initial beneficial ownership by a reporting person who is a Director. The filing reports 0 shares of Common Stock beneficially owned (Direct) and no derivative securities listed in Table II. The date of the event requiring the statement is 10/06/2025, and the form was filed by one reporting person. The submission is signed by Karen Peacock on 10/14/2025.
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated October 7, 2025. The election was disclosed on Form 8-K filed with the Commission and attached as Exhibit 99.1. The filing is signed by Sharon E. Underberg, Executive Vice President, General Counsel and Corporate Secretary. No additional details about director background, committee assignments, or changes to board composition were included in the filing.
Idexx Laboratories insider Form 4: Jonathan Jay Mazelsky, identified as President and CEO and a director, reported a disposal of 1,051 shares of Idexx common stock on 08/15/2025. The form shows 1,051 shares disposed and 82,443.3016 shares beneficially owned following the transaction. The filing was signed by Lily J. Lu as Attorney-in-Fact on 09/04/2025.
Martin A. Smith, Executive Vice President of IDEXX Laboratories (IDXX), reported insider transactions dated 09/01/2025. The filing shows an acquisition of 18 shares of IDEXX common stock and a disposition of 5 shares, leaving reported beneficial ownership figures of 1,438.659 and 1,433.659 shares after each transaction respectively. The filing also records 18 restricted stock units (RSUs) tied to those shares; the RSU grant vests in four annual installments beginning September 1, 2022 and represents contingent rights to one share each. The filing discloses that 28.709 shares were purchased earlier under the issuer’s Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. A price of $647.09 is shown for the disposed shares, noted as the Nasdaq closing price on August 29, 2025. The form is signed by an attorney-in-fact on behalf of Mr. Smith.